News
NTLA
20.76
+3.70%
0.74
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 1d ago
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $29 Price Target
Benzinga · 3d ago
Weekly Report: what happened at NTLA last week (0415-0419)?
Weekly Report · 4d ago
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha · 04/19 07:54
Intellia Therapeutics Welcomes New Principal Accounting Officer
TipRanks · 04/15 20:32
Weekly Report: what happened at NTLA last week (0408-0412)?
Weekly Report · 04/15 12:17
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Pacira Pharmaceuticals (PCRX), Legend Biotech and Intellia Therapeutics (NTLA) have been recommended by 3 analysts with bullish sentiments. RBC Capital maintained a Buy rating on Pacira and Cantor Fitzgerald initiated coverage on the 3 Healthcare stocks. The analysts are bullish on the Healthcare sector as a whole.
TipRanks · 04/09 01:50
Weekly Report: what happened at NTLA last week (0401-0405)?
Weekly Report · 04/08 12:23
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at NTLA last week (0325-0329)?
Weekly Report · 04/01 12:19
Weekly Report: what happened at NTLA last week (0318-0322)?
Weekly Report · 03/25 12:23
Intellia opts out of hemophilia pact with Regeneron
Intellia opts out of hemophilia pact with Regeneron Pharmaceuticals to co-develop a factor IX gene editing therapy. The agreement was signed in 2020. Shares of Intellia Therapeutics, Inc. Were down around 3% on Friday .
Seeking Alpha · 03/22 16:40
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
Intellia Therapeutics has decided to withdraw from its 2020 collaboration with Regeneron Pharmaceuticals on developing gene editing treatments. The two companies will end their shared funding and development responsibilities in six months. Intellia will still support Regeneron under a previous 2016 agreement.
TipRanks · 03/22 13:42
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
NASDAQ · 03/19 17:06
Benjamin Graham Detailed Fundamental Analysis - NTLA
NASDAQ · 03/18 18:06
Weekly Report: what happened at NTLA last week (0311-0315)?
Weekly Report · 03/18 12:21
Weekly Report: what happened at NTLA last week (0304-0308)?
Weekly Report · 03/11 12:16
Weekly Report: what happened at NTLA last week (0226-0301)?
Weekly Report · 03/04 12:20
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
Biotech companies develop therapies for previously untreatable diseases. These companies generally witness considerable stock price growth on successfully developing a drug. The best biotech stocks carry several risks. These five stocks have received a Strong Buy rating from analysts and have upside potential of more than 20%.
TipRanks · 03/04 05:20
Analysts Anticipate ESML Will Reach $43
NASDAQ · 03/01 11:53
More
Webull provides a variety of real-time NTLA stock news. You can receive the latest news about Intellia Therape through multiple platforms. This information may help you make smarter investment decisions.
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.